Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors potentially useful for the treatment of cancer have been described in a recent Scorpion Therapeutics Inc. patent.
Augusta University has patented NSAID derivatives acting as prostaglandin G/H synthase 1 (PTGS1; COX-1) and/or COX-2 inhibitors potentially useful for the treatment of inflammation and pain.
Work at Duke University has led to the discovery of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors potentially useful for the treatment of cancer and gram-negative bacterial infections.
Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK1/cyclin B and/or CDK2/cyclin E1 and/or CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors, reported to be useful for the treatment of cancer.
Virginia Commonwealth University has identified cholestenoic acid derivatives reported to be useful for the treatment of cancer, sepsis, atherosclerosis and nonalcoholic fatty liver disease (NAFLD; metabolic dysfunction-associated steatotic liver disease [MASLD]).
Insilico Medicine Hong Kong Ltd. has synthesized ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer and viral infection.
Dana-Farber Cancer Institute Inc. has disclosed covalent inhibitors of serine/threonine-protein kinase A-Raf (ARAF) reported to be useful for the treatment of carcinoma and melanoma.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators potentially useful for the treatment of epilepsy and depression.